Recognify Life Sciences News Today

To transform the treatment of mental health, clinical-stage biotech atai Life Sciences is peering into the world of psychedelics

/PRNewswire/ -- DelveInsights Schizophrenia Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and pipeline...

Increase in Research and Development activities for advancements in anti-psychotic drugs, product launches, and approvals has increased the Schizophrenia market. An increase in the development

Investegate announcements from atai Life Sciences, atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

Investegate announcements from atai Life Sciences, atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

- Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive

RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial

Investegate announcements from atai Life Sciences, atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia

-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment- -Received...

Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offer...